-
Innovation Ranking
Innovation Ranking – Orion Corp(G)
Orion Corp (Orion) develops, manufactures and markets human and veterinary pharmaceuticals, and active pharmaceutical ingredients (APIs). Its products include pharmaceuticals for the treatment of central nervous system disorders, cancer and respiratory diseases. The company's pipeline encompasses investigational candidates for the treatment of amyotrophic lateral sclerosis, Parkinson’s disease, chronic obstructive pulmonary disease, and various cancer types. Orion’s client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics and laboratories. The company sells its...
-
Innovation Ranking
Innovation Ranking – KT&G Corp
KT&G Corp (KT&G) produces, distributes and sells tobacco, ginseng, health food, cosmetics and pharmaceuticals products. The company’s products portfolio consists of red ginseng, food and beverages, over-the-counter medicines and medical supplies and equipment’s. It also distributes materials related to tobacco business. KT&G markets these products under various brands including, Esse, Carnival, Bohem, Raison, This, Tonino Lamborghini, Time, and Pine. _x000D_ It is also involved in real estate, rental and house development business, leaf tobacco cultivation and trading related activities. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – G-207 in Ependymoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - G-207 in Ependymoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Ependymoma Drug Details: G-207 is under development for high-grade glioma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – G-207 in Gliosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - G-207 in Gliosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Gliosarcoma Drug Details: G-207 is under development for high-grade glioma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – G-207 in Supratentorial Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - G-207 in Supratentorial Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Supratentorial Glioma Drug Details: G-207 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – G-207 in Germ Cell Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - G-207 in Germ Cell Tumors report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Germ Cell Tumors Drug Details: G-207 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – G-207 in Primitive Neuroectodermal Tumor (PNET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - G-207 in Primitive Neuroectodermal Tumor (PNET) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Primitive Neuroectodermal Tumor (PNET) Drug Details: G-207...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – G-207 in Atypical Teratoid Rhabdoid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - G-207 in Atypical Teratoid Rhabdoid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Atypical Teratoid Rhabdoid Tumor Drug Details: G-207...
-
Product Insights
Prostaglandin G/H Synthase 2 – Drugs In Development, 2023
Global Markets Direct’s Prostaglandin G/H Synthase 2 provides in depth analysis on Prostaglandin G/H Synthase 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin G/H Synthase...
-
Product Insights
Prostaglandin G/H Synthase 1 – Drugs In Development, 2023
Global Markets Direct’s Prostaglandin G/H Synthase 1 provides in depth analysis on Prostaglandin G/H Synthase 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin G/H Synthase...